Paradigm Biocapital Advisors as of June 30, 2025
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 28 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 17.2 | $402M | 5.3M | 76.30 | |
| Arcellx Common Stock (ACLX) | 13.1 | $306M | 4.6M | 65.85 | |
| Merus N V (MRUS) | 9.6 | $225M | 4.3M | 52.60 | |
| Revolution Medicines (RVMD) | 9.6 | $224M | 6.1M | 36.79 | |
| Tarsus Pharmaceuticals (TARS) | 5.1 | $121M | 3.0M | 40.51 | |
| Vaxcyte (PCVX) | 4.7 | $110M | 3.4M | 32.51 | |
| Beone Medicines Sponsored Ads (ONC) | 3.6 | $84M | 348k | 242.07 | |
| Edgewise Therapeutics (EWTX) | 3.4 | $81M | 6.1M | 13.11 | |
| Cogent Biosciences (COGT) | 3.2 | $74M | 10M | 7.18 | |
| Janux Therapeutics (JANX) | 2.9 | $68M | 2.9M | 23.10 | |
| Crinetics Pharmaceuticals In (CRNX) | 2.9 | $67M | 2.3M | 28.76 | |
| Disc Medicine (IRON) | 2.7 | $64M | 1.2M | 52.96 | |
| Scholar Rock Hldg Corp (SRRK) | 2.4 | $57M | 1.6M | 35.42 | |
| Lenz Therapeutics (LENZ) | 2.1 | $50M | 1.7M | 29.31 | |
| Bridgebio Pharma (BBIO) | 1.8 | $42M | 966k | 43.18 | |
| Apogee Therapeutics (APGE) | 1.8 | $42M | 959k | 43.43 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.8 | $42M | 878k | 47.20 | |
| Alkermes SHS (ALKS) | 1.7 | $39M | 1.4M | 28.61 | |
| Miragen Therapeutics (VRDN) | 1.6 | $38M | 2.7M | 13.98 | |
| Agios Pharmaceuticals (AGIO) | 1.6 | $38M | 1.1M | 33.26 | |
| Ocular Therapeutix (OCUL) | 1.4 | $32M | 3.4M | 9.28 | |
| Olema Pharmaceuticals (OLMA) | 1.2 | $29M | 6.8M | 4.26 | |
| Spyre Therapeutics Com New (SYRE) | 1.2 | $28M | 1.9M | 14.97 | |
| Y Mabs Therapeutics | 0.8 | $19M | 4.2M | 4.51 | |
| Pharvaris N V (PHVS) | 0.8 | $19M | 1.1M | 17.60 | |
| Immatics SHS (IMTX) | 0.7 | $17M | 3.1M | 5.38 | |
| Erasca (ERAS) | 0.6 | $15M | 12M | 1.27 | |
| Crescent Biopharma (CBIO) | 0.4 | $10M | 643k | 16.14 |
